Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%.
Novartis' Fabhalta slows progression of rare kidney disease in trial
Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX showed unprecedented reversal of cirrhosis and significant fibrosis improvement in the HARMONY and SYMMETRY studies, respectively, positioning it as a leader in FGF21 analogs. The acquisition includes $54 per share upfront as cash and a $6 per share CVR contingent on FDA approval for compensated cirrhosis due to MASH patients by 2031.
Here's Why Novartis (NVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Growth Investors Will Love Novartis (NVS)
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales of Scemblix, which is rapidly capturing the chronic myeloid leukemia market, reached $298 million for NVS in the second quarter of 2025, an increase of 81.7% year-on-year. Also, I was pleased to see that NVS repurchased $2.71 billion worth of its shares in Q2 2025, a 68% increase year-on-year.
US FDA approves Novartis' drug for skin disease
The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
Novartis has stockpiles to withstand potential Trump tariffs, CEO says
Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump's tariffs, its chief executive said in an interview published on Saturday.
